Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 618

1.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2018 Jul 9. doi: 10.1038/s41409-018-0264-8. [Epub ahead of print] Review.

PMID:
29988062
2.

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV.

Blood Cancer J. 2018 Jul 6;8(7):67. doi: 10.1038/s41408-018-0102-7.

3.

Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, Kourelis T, Arendt B, Merlini G, Ramirez-Alvarado M, Dispenzieri A.

Leukemia. 2018 Jul 6. doi: 10.1038/s41375-018-0194-x. [Epub ahead of print] No abstract available.

PMID:
29977017
4.

Prognostic significance of stringent complete response post stem cell transplantation in AL amyloidosis.

Sidiqi MH, Aljama M, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M.

Biol Blood Marrow Transplant. 2018 Jun 29. pii: S1083-8791(18)30366-5. doi: 10.1016/j.bbmt.2018.06.027. [Epub ahead of print]

PMID:
29964192
5.

Autologous stem cell transplant for AL amyloidosis patients aged 70 to 75.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2018 Jun 19. pii: S1083-8791(18)30329-X. doi: 10.1016/j.bbmt.2018.06.017. [Epub ahead of print]

PMID:
29933071
6.

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.

7.

A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference.

Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL.

Blood. 2018 Jun 11. pii: blood-2018-05-848986. doi: 10.1182/blood-2018-05-848986. [Epub ahead of print] No abstract available.

PMID:
29891533
8.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1037-1046. doi: 10.2215/CJN.13041117. Epub 2018 May 30.

PMID:
29848505
9.

A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.

Dumontet C, Hulin C, Dimopoulos MA, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T.

Leukemia. 2018 Jun;32(6):1404-1413. doi: 10.1038/s41375-018-0133-x. Epub 2018 Apr 26.

10.

Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M.

Circ Cardiovasc Imaging. 2018 May;11(5):e006588. doi: 10.1161/CIRCIMAGING.117.006588.

PMID:
29752392
11.

MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis.

Illman JE, Arunachalam SP, Arani A, Chang IC, Glockner JF, Dispenzieri A, Grogan M, Araoz PA.

Amyloid. 2018 May 7:1-8. doi: 10.1080/13506129.2018.1465406. [Epub ahead of print]

PMID:
29733684
12.

Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA.

Br J Haematol. 2018 Jul;182(1):71-77. doi: 10.1111/bjh.15244. Epub 2018 Apr 29.

PMID:
29707759
13.

Outcomes after Cardiac Transplant for Wild Type Transthyretin Amyloidosis.

Rosenbaum AN, Abou Ezzeddine OF, Grogan M, Dispenzieri A, Kushwaha S, Clavell A, Daly RC, Edwards BS.

Transplantation. 2018 Apr 19. doi: 10.1097/TP.0000000000002240. [Epub ahead of print]

PMID:
29677073
14.

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.

Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M.

Haematologica. 2018 Jul;103(7):1229-1234. doi: 10.3324/haematol.2018.189985. Epub 2018 Apr 19.

15.

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK.

Am J Hematol. 2018 Jul;93(7):889-894. doi: 10.1002/ajh.25113.

PMID:
29659048
16.

Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Kyle RA, Larson DR, McPhail ED, Therneau TM, Dispenzieri A, Kumar S, Kapoor P, Cerhan JR, Rajkumar SV.

Mayo Clin Proc. 2018 Jun;93(6):739-746. doi: 10.1016/j.mayocp.2018.02.011. Epub 2018 Apr 12.

PMID:
29656787
17.

Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.

Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, Kumar SK.

Biol Blood Marrow Transplant. 2018 Apr 12. pii: S1083-8791(18)30188-5. doi: 10.1016/j.bbmt.2018.04.007. [Epub ahead of print]

PMID:
29656139
18.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kumar SK, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA.

Blood Adv. 2018 Apr 10;2(7):769-776. doi: 10.1182/bloodadvances.2018016782.

19.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P.

Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3.

PMID:
29610969
20.

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2018 Feb 20. doi: 10.1038/s41375-018-0060-x. [Epub ahead of print]

PMID:
29581546
21.

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance.

Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Leukemia. 2018 Jan 30. doi: 10.1038/s41375-018-0030-3. [Epub ahead of print] No abstract available.

PMID:
29568092
22.

The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Leukemia. 2018 May;32(5):1243-1246. doi: 10.1038/s41375-018-0022-3. Epub 2018 Jan 30. No abstract available.

PMID:
29568089
23.

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ, Gertz MA.

J Clin Oncol. 2018 May 1;36(13):1323-1329. doi: 10.1200/JCO.2017.76.9554. Epub 2018 Mar 20.

PMID:
29558277
24.

Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?

Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Dingli D, Rajkumar SV, Dispenzieri A, Grogan M.

Amyloid. 2018 Mar 12:1-7. doi: 10.1080/13506129.2018.1449744. [Epub ahead of print]

PMID:
29529877
25.

Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI.

Leukemia. 2018 Jun;32(6):1421-1426. doi: 10.1038/s41375-018-0063-7. Epub 2018 Feb 21.

PMID:
29483709
26.

Opening a can of worms in AL progression.

Dispenzieri A.

Blood. 2018 Feb 1;131(5):475-476. doi: 10.1182/blood-2017-11-815423. No abstract available.

PMID:
29437606
27.

Aortic valve replacement in patients with amyloidosis.

Java AP, Greason KL, Dispenzieri A, Grogan M, King KS, Maleszewski JJ, Daly RC, Eleid MF, Pochettino A, Schaff HV.

J Thorac Cardiovasc Surg. 2018 Jul;156(1):98-103. doi: 10.1016/j.jtcvs.2017.12.048. Epub 2017 Dec 19.

PMID:
29397971
28.

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.

Leung N, Thomé SD, Dispenzieri A.

Haematologica. 2018 Mar;103(3):e135-e137. doi: 10.3324/haematol.2017.183749. Epub 2018 Jan 19. No abstract available.

29.

Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, Rajkumar SV.

N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974.

PMID:
29342381
30.

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.

Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ.

Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012.

PMID:
29304921
31.

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis.

Sidana S, Tandon N, Gertz MA, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2018 Mar;53(3):326-333. doi: 10.1038/s41409-017-0020-5. Epub 2017 Dec 21.

PMID:
29269795
32.

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A.

Leukemia. 2018 Apr;32(4):986-995. doi: 10.1038/leu.2017.331. Epub 2017 Nov 16.

33.

Reply.

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS.

Am J Ophthalmol. 2018 Feb;186:170. doi: 10.1016/j.ajo.2017.11.005. Epub 2017 Dec 13. No abstract available.

PMID:
29248199
34.

Outcomes of Patients With Familial Transthyretin Amyloidosis After Liver Transplantation.

Banerjee D, Roeker LE, Grogan M, Swiecicki P, Poterucha J, Heimbach J, Zeldenrust S, Gertz M, Edwards B, Daly R, Klarich KW, Dispenzieri A.

Prog Transplant. 2017 Sep;27(3):246-250. doi: 10.1177/1526924817715463. Epub 2017 Jul 4.

PMID:
29187090
35.

POEMS Syndrome: Diagnosis and Investigative Work-up.

Dispenzieri A, Kourelis T, Buadi F.

Hematol Oncol Clin North Am. 2018 Feb;32(1):119-139. doi: 10.1016/j.hoc.2017.09.010. Review.

PMID:
29157614
36.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

37.

Importance of FISH genetics in light chain amyloidosis.

Gertz MA, Dispenzieri A, Muchtar E.

Oncotarget. 2017 Sep 19;8(47):81735-81736. doi: 10.18632/oncotarget.21052. eCollection 2017 Oct 10. No abstract available.

38.

Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Gertz MA.

Bone Marrow Transplant. 2018 Feb;53(2):155-161. doi: 10.1038/bmt.2017.228. Epub 2017 Nov 13.

PMID:
29131152
39.

Skull base plasmacytoma: A unique case of POEMS syndrome with a plasmacytoma causing craniocervical instability.

Gilder H, Murphy ME, Alvi MA, Kerezoudis P, Shepherd D, Maloney PR, Yaszemski MJ, Morris JM, Dispenzieri A, Matsumoto JM, Bydon M.

J Clin Neurosci. 2018 Jan;47:254-257. doi: 10.1016/j.jocn.2017.10.038. Epub 2017 Oct 31.

PMID:
29100675
40.

DnaJ Heat Shock Protein Family B Member 9 Is a Novel Biomarker for Fibrillary GN.

Dasari S, Alexander MP, Vrana JA, Theis JD, Mills JR, Negron V, Sethi S, Dispenzieri A, Highsmith WE Jr, Nasr SH, Kurtin PJ.

J Am Soc Nephrol. 2018 Jan;29(1):51-56. doi: 10.1681/ASN.2017030306. Epub 2017 Nov 2.

PMID:
29097623
41.

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P.

Am J Hematol. 2018 Feb;93(2):187-194. doi: 10.1002/ajh.24955. Epub 2017 Nov 17.

PMID:
29080258
42.

Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects.

Jiang H, Schmit NR, Koenen AR, Bansal A, Pandey MK, Glynn RB, Kemp BJ, Delaney KL, Dispenzieri A, Bakkum-Gamez JN, Peng KW, Russell SJ, Gunderson TM, Lowe VJ, DeGrado TR.

EJNMMI Res. 2017 Oct 27;7(1):90. doi: 10.1186/s13550-017-0337-5.

43.

OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS.

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS.

Retina. 2018 Jul;38(7):1371-1376. doi: 10.1097/IAE.0000000000001901.

PMID:
29068915
44.

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.

Lakshman A, Singh PP, Rajkumar SV, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Hwa YL, Fonder AL, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK.

Am J Hematol. 2018 Feb;93(2):179-186. doi: 10.1002/ajh.24954. Epub 2017 Nov 10.

PMID:
29067723
45.

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.

Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, Mailankody S, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV.

Blood Cancer J. 2017 Oct 20;7(10):e618. doi: 10.1038/bcj.2017.97.

46.

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).

Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Buadi FK, Fonder AL, Hayman SR, Hwa YL, Hobbs MA, Kapoor P, Gonsalves WI, Leung N, Go RS, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Kumar SK.

Am J Hematol. 2018 Jan;93(1):17-22. doi: 10.1002/ajh.24919. Epub 2017 Oct 20.

PMID:
28960427
47.

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Lust JA, Russell SJ, Zeldenrust SR, Rajkumar SV, Kumar SK.

Leukemia. 2018 Mar;32(3):729-735. doi: 10.1038/leu.2017.286. Epub 2017 Sep 18.

PMID:
28919633
48.

Ocular Manifestations of Familial Transthyretin Amyloidosis.

Reynolds MM, Veverka KK, Gertz MA, Dispenzieri A, Zeldenrust SR, Leung N, Pulido JS.

Am J Ophthalmol. 2017 Nov;183:156-162. doi: 10.1016/j.ajo.2017.09.001. Epub 2017 Sep 11.

PMID:
28911993
49.

A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE.

Bone Marrow Transplant. 2017 Oct;52(10):1372-1377. doi: 10.1038/bmt.2017.164. Epub 2017 Sep 4.

PMID:
28869617
50.

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK.

Blood Cancer J. 2017 Sep 1;7(9):e600. doi: 10.1038/bcj.2017.83.

Supplemental Content

Loading ...
Support Center